ABL, a pioneer in the development,
manufacturing and release of viral vectors
offers its customers a unique expertise.
We work in close and transparent relationship
with our customers to mitigate the CMC challenges
to go to their dossier submission
and approval for commercial launch.
From development to market
we provide GMP viral vectors,
contributing to the success of
our clients’ immunotherapy innovations.